Parkinson’s study, Gilead, CG Oncology

The article discusses various developments in the biotech industry, including the challenges faced by venture capitalists, Gilead Sciences’ investment in oncology, an upcoming IPO for an obesity-related company, and new research in Parkinson’s disease treatments. It also mentions other relevant news and offers readers the option to sign up for a biotech newsletter. The industry is facing funding challenges, making it crucial for companies to succeed in IPOs. Gilead Sciences may need to shift its focus in oncology, while new research in Parkinson’s disease is providing hope for potential new treatments.

Source link

error: Content is protected !!